-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Futibatinib in Extrahepatic Bile Duct Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Futibatinib in Extrahepatic Bile Duct Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Futibatinib in Extrahepatic Bile Duct Cancer Drug Details: Futibatinib...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Futibatinib in Pancreatic Ductal Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Futibatinib in Pancreatic Ductal Adenocarcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Futibatinib in Pancreatic Ductal Adenocarcinoma Drug Details: Futibatinib (Lytgobi) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Taladegib in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Taladegib in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Taladegib in Solid Tumor Drug Details: Taladegib (LY-2940680) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Taladegib in Idiopathic Pulmonary Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Taladegib in Idiopathic Pulmonary Fibrosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Taladegib in Idiopathic Pulmonary Fibrosis Drug Details: Taladegib (LY-2940680) is...
-
Product Insights
Oswego Harbor Power Plant
Oswego Harbor Power Plant is a thermal project located in New York, United States. The project is owned by Generation Bridge LLC. The project came online in 1975. Empower your strategies with our Oswego Harbor Power Plant report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of the report may...
-
Product Insights
Grays Harbor Power Plant
Grays Harbor Power Plant is a thermal project located in Washington, United States. The project is owned by Grays Harbor Energy LLC and is developed by Grays Harbor Energy LLC; Invenergy LLC. The project is partially active. Empower your strategies with our Grays Harbor Power Plant report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding...
-
Product Insights
Outer Harbor Power Project
Outer Harbor Power Project is a thermal project located in South Australia, Australia. The project is owned and being developed by Venice Energy Pty Ltd. The project is at the permitting stage. Empower your strategies with our Outer Harbor Power Project report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zenocutuzumab in Metastatic Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zenocutuzumab in Metastatic Breast Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Zenocutuzumab in Metastatic Breast Cancer Drug Details: Zenocutuzumab (MCLA-128) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zenocutuzumab in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zenocutuzumab in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Zenocutuzumab in Solid Tumor Drug Details: Zenocutuzumab (MCLA-128) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zenocutuzumab in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zenocutuzumab in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Zenocutuzumab in Non-Small Cell Lung Cancer Drug Details: Zenocutuzumab (MCLA-128)...